Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 101 to 150 of 304

TitleType
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidance
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Technology appraisal guidance
Galcanezumab for migraine TS ID 10663Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease TS ID 10668Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Technology appraisal guidance
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Technology appraisal guidance
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donorsInterventional procedures guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]Technology appraisal guidance
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failureInterventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmiasInterventional procedures guidance
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Technology appraisal guidance
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancerInterventional procedures guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidance
LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidance
LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All